← All stocks

AN2 Therapeutics, Inc.

ANTX Net selling

CIK 0001880438 #3872 in the set updated 17 Sep 2026

Bought (12 mo)

$11.60K

out of their own pocket, the only kind of buying there is

Sold (12 mo)

$398.30K

$316.70K on a plan · $0.00 straight out of an exercise

Sold at will

$81.60K

14 of 22 sales

Net

−$386.70K

−$70.00K against sales at will

By person

14 insiders · 23 transactions

14.3×

Eric Easom holds 14.3 times base salary in stock. $8.64M of shares against $603.75K in salary for 2025.

Salary from the company's own proxy. The shares are what Eric Easom last reported holding, valued at $6.02, the price Common Stock was last bought or sold at on the open market here, on 9 Sep 2026.

Insider

Role

Bought

Sold

Net

Holding

Of company

Worth

Change

Readnour Robin Shane

Director

—

$316.70K (8) scheduled

−$316.70K

1,267,709

3.36%

$7.64M

+29.9%

Eizen Joshua M

See Remarks

—

$52.98K (4)

−$52.98K

206,554

0.5474%

$1.24M

+88.1%

FitzPatrick Margaret M

Director

$11.60K (1)

—

+$11.60K

10,708

0.0284%

$64.51K

—

Chanda Sanjay

Chief Development Officer

—

$9.33K (2)

−$9.33K

118,823

0.3149%

$715.83K

+177.7%

Day Lucy

Chief Financial Officer

—

$8.88K (2)

−$8.88K

118,363

0.3137%

$713.05K

+159.4%

Prior Stephen David

Chief Strategy Officer

—

$7.38K (3)

−$7.38K

59,086

0.1566%

$355.95K

+95.5%

Williams Sarah Joanne

Principal Accounting Officer

—

$3.02K (3)

−$3.02K

66,311

0.1757%

$399.48K

+252.7%

Leonard Braden Michael

10% owner

—

3,217,432

8.53%

$19.38M

−45.9%

Easom Eric

Chief Executive Officer

—

1,434,396

3.80%

$8.64M

+28.4%

Zakrzewski Joseph S

Director

—

145,538

0.3857%

$876.76K

−71.1%

Trenor Cameron C. III

Chief Medical Officer

—

116,667

0.3092%

$702.84K

—

Marks Gilbert Lynn

Director

—

81,873

0.2170%

$493.23K

+258.6%

Aziz Kabeer

Director

—

59,106

0.1566%

$356.07K

—

Martin Patricia A.

Director

—

18,863

0.0500%

$113.64K

—

AN2 Therapeutics, Inc.

By person

Individual transactions

What was left out